Tadalafil 60 mg contains tadalafil, a PDE5 inhibitor. This strength is above standard approved erectile dysfunction and PAH regimens and requires regulatory verification and specialist medical assessment.
| Category | ED Medicine |
|---|---|
| Available at | Washington, USA, Canbbera, Australia, London, UK, Singapore, Singapore, Nagpur, India |
Tadalafil 60 mg Tablets contain tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor associated with the management of certain medical conditions, including erectile dysfunction and pulmonary arterial hypertension at established approved doses.
Tadalafil works by inhibiting the PDE5 enzyme and influencing blood-vessel relaxation through the nitric oxide pathway. Its established erectile dysfunction regimens include 2.5 mg and 5 mg for daily treatment and 5 mg, 10 mg, or 20 mg for as-needed treatment.
Important safety and regulatory information: Tadalafil 60 mg is not a standard recommended dose for erectile dysfunction or the established 40 mg daily PAH regimen. Higher exposure may increase the risk of adverse effects, including headache, dizziness, flushing, low blood pressure, and prolonged erection. This strength must not be presented as a stronger or more effective routine ED treatment.
Product availability, formulation, and authorization must be independently verified in the applicable market before commercial distribution.
Vision Pharma supports pharmaceutical product enquiries and sourcing discussions with authorized distributors, importers, and international pharmaceutical businesses.
Official websites:
- https://www.visionpharmaexport.com/
- https://www.visionpharmaglobal.co.in/
Contact:
- Email: visionpharmaglobal@gmail.com
- Phone: +91 9326646654
Tadalafil 60 mg tablets contain tadalafil, a PDE5 inhibitor. This strength is above standard recommended erectile dysfunction and established PAH dosing regimens.
No. The maximum recommended as-needed ED dose in standard prescribing guidance is 20 mg. Tadalafil 60 mg is not a standard recommended ED dosage.
Tadalafil inhibits the PDE5 enzyme, helping regulate blood-vessel relaxation and improve blood flow in response to natural nitric oxide signaling.
Higher exposure may increase the risk of headache, dizziness, flushing, low blood pressure, and prolonged erection.
No. This strength requires specialist medical assessment and verification of its regulatory authorization. It should not be self-administered.
Buyers can contact Vision Pharma for product information and regulatory enquiries, subject to applicable product authorization.
Contact visionpharmaglobal@gmail.com or +91 9326646654 for pharmaceutical business enquiries.
Tell us the product name, quantity and your country. We reply by phone or email.
